Qiming Venture Partners

🔊 Looking back, what Qiming Venture Partners has achieved? Find out more in 60 seconds.

At the Ninth China Biomed Innovation and Investment Conference, Qiming Venture Partners' Partner and Healthcare Co-Lead kan chen, PhD delivered a keynote exploring the remarkable progress of China's pharmaceutical innovations, the strategies driving its globalization, and the challenges and opportunities it has encountered along the way. China's biotech sector is entering a new phase of globalization, with licensing-out deals reaching record highs (2020-2023). For the first time, the value of these deals has surpassed traditional financing, creating a sustainable cycle of innovation and development. These landmark achievements highlight the growing competitiveness of Chinese pharmaceutical companies. Kan emphasized China's competitive advantages—rapid innovation in crowded markets and breakthrough first-in-class developments, powered by efficient clinical trials and strong R&D capabilities. He also outlined diverse global expansion models—including licensing-out, asset purchase, co-development, and NewCo models—and discussed their pros and cons. He analyzed the current challenges and recommended that Chinese biotech firms consider embracing global collaborative strategies to transition from a China-focused approach to global innovation. This transition aims to provide high-quality, efficient medical products and services to patients worldwide, thereby contributing to the development of global healthcare. For more insights on China's evolving pharmaceutical innovation and investment outlook, read the full keynote below. #BiotechInnovation #PharmaceuticalIndustry #GlobalHealthcare #VentureCapital #ClinicalTrials #DrugDevelopment #HealthcareInvestment #BiomedConference #ChineseBiotech #QimingInsights

DH-Robotics, a portfolio company of Qiming Venture Partners, has launched the DLE Series Direct Drive Linear Modules, designed to drive innovation in precision assembly and testing. These modules are ideal for processes in industries such as consumer electronics, including insertion and extraction testing, compression testing, alignment, pushing, and line scanning. The DLE Series can be customized to meet specific production needs, either with a single unit or multiple modules, in conjunction with the SAC-N2 Dual-Axis Driver. For example, in mobile phone charging port aging tests, the DLE Series performs over 10,000 repetitive insertion and extraction cycles, capturing force variation data during each cycle. A standout feature of the DLE Series is its open-loop force control, which helps reduce the need for additional sensors and minimizes the equipment footprint. During these tests, it provides real-time feedback through force-displacement curves. With adjustable force settings, it adapts to various working conditions. The system also alerts users immediately if force or displacement anomalies occur. #PrecisionEngineering #ManufacturingInnovation #Automation #Robotics #TestingSolutions #SmartManufacturing #Industry4.0 #TechnologyAdvancements #EngineeringExcellence #QimingPortfolio #QimingTechnology

Aohua Endoscopy Co., Ltd. (SHSE: 688212), a portfolio company of Qiming Venture Partners, announced the launch of the VLT-N300H Electronic Thoracoscope. This advanced technology offers a new solution for diagnosing and treating thoracic and pleural diseases. The VLT-N300H boasts a rigid insertion section for improved force transmission to the tip, while its slim 6.8mm diameter allows easy passage through intercostal spaces with minimal trauma. The flexible tip reduces irritation to the intercostals, and with 180° of upward and downward bending and 120° rotation, it provides greater maneuverability and a broader field of view. Designed with a large working channel, the VLT-N300H accommodates a range of therapeutic tools, offering surgeons more flexibility during procedures. It also provides strong suction power for clear visibility, especially during fluid or blood drainage. The thoracoscope is effective for diagnosing and treating various thoracic conditions, including pulmonary nodules, lung tumors, pleural diseases, pneumothorax, and pleural effusion. Additionally, it supports various treatment methods, such as laser and high-frequency electrical therapy. #MedicalInnovation #Thoracoscopy #Endoscopy #HealthcareTechnology #SurgicalInnovation #MedicalDevices #QimingPortfolio #QimingHealthcare

Zai Lab (NASDAQ: ZLAB, SEHK: 9688), a portfolio company of Qiming Venture Partners, announced that the first prescription of AUGTYRO® (repotrectinib) in China has been issued, providing a new treatment option for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). AUGTYRO® was recently included in China's updated National Reimbursement Drug List (NRDL), effective January 1, 2025, increasing patient access to this innovative therapy. As a next-generation tyrosine kinase inhibitor (TKI), repotrectinib targets the ROS1 oncogene and features a unique compact macrocyclic structure. This design helps to overcome ROS1 resistance mutations, offering new hope for TKI-naive and TKI-pretreated patients with ROS1-positive advanced NSCLC. #NSCLC #CancerTreatment #PrecisionMedicine #HealthcareInnovation #Repotrectinib #ROS1 #TKI #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company, M20 Genomics, recently collaborated with Nature Portfolio to host the "Nature Masterclass – Editors' Workshop" in Shanghai. This in-person event brought together researchers from across China, offering a unique opportunity to engage directly with senior editors from Nature series journals. Participants gained valuable insights and expert advice on crafting high-quality academic papers. As part of its commitment to supporting research excellence, M20 Genomics goes beyond providing advanced single-cell transcriptomics solutions. By partnering with leading academic publishers like Springer Nature, M20 Genomics facilitates meaningful connections between research teams and professional editors. This initiative is designed to enhance research quality, boost publication success rates, and empower researchers to succeed in today's competitive academic environment. #LifeSciences #ResearchExcellence #ScientificPublishing #Innovation #SingleCellTechnology #NatureMasterclass #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company, IntoCare Medical, recently hosted the IntoCare Intelligence Nexus Transcontinental Conversation, a Sino-French academic exchange event on colorectal surgery, at Ruijin Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine in Shanghai. This prestigious forum not only strengthened medical collaboration between China and France but also set a new standard for innovation and progress in the field of colorectal surgery. The event featured renowned experts, including Prof. Quentin Denost from France's Bordeaux Colorectal Institute and Prof. Minhua Zheng's team from Ruijin Hospital, who engaged in insightful discussions on the latest advancements and clinical practices. Topics included sphincter-preserving surgery for rectal cancer, minimally invasive treatments, and innovative techniques like TTSS. These exchanges provided fresh perspectives and contributed to significant academic progress in the field. #GlobalCollaboration #ColorectalSurgery #MinimallyInvasiveSurgery #MedicalInnovation #HealthcareExcellence #SinoFrenchPartnership #AcademicExcellence #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company Berry Genomics (SZSE:000710) has launched a pioneering genetic testing solution for Autosomal Dominant Polycystic Kidney Disease (ADPKD) using advanced third-generation sequencing technology. This state-of-the-art solution offers precise detection of gene mutations, comprehensively covering complex mutation types to enable accurate diagnosis. Given the strong correlation between ADPKD phenotypes and mutation types, genetic testing plays a vital role in achieving precise diagnosis and guiding effective treatment. Berry Genomics' solution provides full coverage of all 46 exons of the PKD1 gene and all 15 exons of the PKD2 gene. Its advanced primer combinations enable the detection of a wide range of mutations, including point mutations, intragenic deletions/duplications, and large fragment deletions. By amplifying true PKD1 gene fragments while eliminating pseudogene interference, it ensures accurate gene identification. With a sequencing accuracy rate of over 99.999% (QV50), this innovation guarantees highly reliable clinical diagnostic results. #Innovation #Genomics #PrecisionMedicine #ADPKD #HealthcareInnovation #ThirdGenerationSequencing #GeneticTesting #MedicalBreakthrough #QimingPortfolio #QimingHealthcare

LanzaTech (NASDAQ: LNZA), a portfolio company of Qiming Venture Partners, has reached an exciting milestone through its collaboration with Technip Energies on the Sustainable Ethylene from CO2 Utilization with Renewable Energy Project (Project SECURE). The initiative was awarded funding of up to $200 million for the commercialization of breakthrough CO2-to-Ethylene technology and authorized to initiate Phase 1 of the project. Project SECURE aims to provide an integrated commercial process that captures carbon dioxide from ethylene production and recycles it with low-carbon-intensity hydrogen to create sustainable ethanol and ethylene. This joint technology solution will first be deployed for integration into an existing commercial ethylene cracker and holds significant replication potential for ethylene crackers worldwide. #Sustainability #CarbonRecycling #CleanEnergy #RenewableEnergy #Innovation #Ethylene #GreenTech #QimingPortfolio #QimingTechnology Read More: https://lnkd.in/gG--hxQU

Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals Inc. (SEHK:1228) announced the marketing approval of Livmarli® (Maralixibat Chloride Oral Solution) by China's Taiwan Food and Drug Administration for treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) patients aged three months and older. LIVMARLI® is a minimally absorbed ileal bile acid transporter (IBAT) inhibitor that blocks the enterohepatic circulation of bile acids, reduces bile acid levels in the liver and serum, reduces the resultant liver injury and relieves pruritus (extreme itching). LIVMARLI® is the first, and only medication approved in China, the US and EU (2 months and older) to treat cholestatic pruritus associated with Alagille syndrome (ALGS) aged 3 months and older. It is also approved in the US for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older and in Europe for the treatment of PFIC in patients three months of age and older. LIVMARLI® has been granted Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS and PFIC by the FDA. #LIVMARLI #CholestaticPruritus #PFIC #AlagilleSyndrome #ProgressiveFamilialIntrahepaticCholestasis #IBATInhibitor #FDAApproved #OrphanDrug #BreakthroughTherapy #RareDisease #MedicalInnovation #Pharmaceuticals #QimingPortfolio #QimingHealthcare